Estamos no ar no ! Saiba mais
ícone de MBOT

Microbot Medical

0,9500 USD
0,0000
0%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
0,9499
-0,0001
0,01%
1 dia
0%
5 dias
-11,21%
1 mês
-34,03%
3 meses
-46,93%
6 meses
-60,25%
No acumulado do ano
-54,98%
1 ano
-66,55%
5 anos
-86,71%
10 anos
-99,24%
 

Sobre: Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.

Funcionários: 22

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 16,7%
Neutro 83,3%
Negativo 0%
Neutro
GlobeNewsWire
há 11 dias
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S. HINGHAM, Mass.
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Neutro
GlobeNewsWire
há 21 dias
Microbot Medical® Highlights Growth Strategy
Service Unavailable Service Unavailable HTTP Error 503. The service is unavailable.
Microbot Medical® Highlights Growth Strategy
Neutro
Zacks Investment Research
há 2 meses
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Neutro
GlobeNewsWire
há 2 meses
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April The Company added new customers in Q3 while expanding into new states and sites of service HINGHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission (SEC).
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Positivo
Zacks Investment Research
há 2 meses
New Strong Buy Stocks for July 23rd
PLGO, BLPD, INN, RFIL and MBOT have been added to the Zacks Rank #1 (Strong Buy) List on July 23, 2026.
New Strong Buy Stocks for July 23rd
Neutro
GlobeNewsWire
há 2 meses
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year's Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort Lauderdale, FL.
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
Neutro
GlobeNewsWire
há 3 meses
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026 HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026.
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Neutro
GlobeNewsWire
há 3 meses
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
Neutro
GlobeNewsWire
há 3 meses
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the Innovative Start-Up Award from Surgical Robotics Technology (SRT), which recognizes companies with outstanding technological and commercial progress through highly innovative, groundbreaking technologies with the potential for broad healthcare impact.1 SRT, a leading platform for surgical robotics news, together with QNX, recognizes outstanding organizations, individuals, and technologies across the surgical robotics sector.
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
Neutro
GlobeNewsWire
há 3 meses
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Leading academic center with multi-hospital and multi-state health system deepens Company's footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LIBERTY System across seven states in the U.S. HINGHAM, Mass., June 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that a globally recognized academic center headquartered in Pennsylvania is the first in the state to adopt the LIBERTY System, allowing the Company to further expand its presence in the Northeast U.S., joining other health systems in New York City and Boston that have also adopted the LIBERTY System.
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Gráficos de preços implementados com Lightweight Charts™